Information Provided By:
Fly News Breaks for October 14, 2015
DYAX
Oct 14, 2015 | 05:57 EDT
Leerink analyst Joseph Schwartz upgraded Dyax to Outperform with a $36 price target citing the company's upcoming pipeline, specifically DX-2930, advancement. DX-2930 is an investigational drug candidate in development for the prevention of hereditary angioedema attacks. Dyax expects to begin a Phase 3 clinical trial by year-end 2015.
News For DYAX From the Last 2 Days
There are no results for your query DYAX
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.